Major shareholders of Newamsterdam Pharma are selling $1.95M worth of shares to Investing.com

Following these transactions, the obligors retain a significant stake in NewAmsterdam Pharma, holding a total of 10,686,018 shares. Despite the sale, the Forbion entities remain major shareholders in the company, with shares held indirectly through their joint venture vehicle, ForGrowth NAP BV. The transactions were part of a structured plan, and the shares were sold in several transactions at prices within the specified ranges. Reporting entities have undertaken to provide full transaction details upon request. For deeper insight into NAMS’s valuation and comprehensive analysis, investors can access the full Pro Research Report available at InvestingProcovering over 1,400 US stocks with expert analysis and actionable intelligence. For deeper insight into NAMS’s valuation and comprehensive analysis, investors can access the full Pro Research Report available at InvestingProcovering over 1,400 US stocks with expert analysis and actionable intelligence.

Following these transactions, the obligors retain a significant stake in NewAmsterdam Pharma, holding a total of 10,686,018 shares. Despite the sale, the Forbion entities remain major shareholders in the company, with shares held indirectly through their joint venture vehicle, ForGrowth NAP BV. The transactions were part of a structured plan, and the shares were sold in several transactions at prices within the specified ranges. Reporting entities have undertaken to provide full transaction details upon request. For deeper insight into NAMS’s valuation and comprehensive analysis, investors can access the full Pro Research Report available at InvestingProcovering over 1,400 US stocks with expert analysis and actionable intelligence.

Following these transactions, the obligors retain a significant stake in NewAmsterdam Pharma, holding a total of 10,686,018 shares. Despite the sale, the Forbion entities remain major shareholders in the company, with shares held indirectly through their joint venture holder, ForGrowth NAP BV

The transactions were part of a structured plan, and the shares were sold in multiple transactions at prices within the specified ranges. Reporting entities have undertaken to provide full transaction details upon request.

In other recent news, NewAmsterdam Pharma Co NV has seen several major developments. The company’s lead drug candidate, obicetrapib, showed promising results in a Phase 3 trial, prompting HC Wainwright, Scotiabank (TSX:), and Leerink Partners to issue positive ratings and raise price targets. The drug showed a significant reduction in LDL-C cholesterol levels and major adverse cardiovascular events.

Furthermore, NewAmsterdam Pharma has suspended and terminated the previously filed ATM Prospectus related to the $150 million share sale plan. The company also restated its financial statements for the years ending 2022 and 2021 due to identified errors in the calculation of net loss per ordinary share and welcomed new board members Mark C. McKenna and Wouter Joustra.

Looking ahead, NewAmsterdam is preparing for the Phase 3 HORIZON trial of pelacarsen in 2025 and the Phase 3 BROADWAY trial, expected in the fourth quarter of 2024. These are recent developments for NewAmsterdam Pharma.

This article was generated with the support of artificial intelligence and reviewed by an editor. See our T&C for more information.